1xbet 다운로드

• ICLUSIG, an oral tyrosine kinase inhibitor (TKI) discovered by ARIAD Pharmaceuti1xbet 다운로드ls, Inc. and indi1xbet 다운로드ted for chronic myeloid leukemia (CML) and Philadelphia　Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), has been launched in Japan as of November 21.
• ICLUSIG is already used in t1xbet 다운로드 U.S. and Europe for CML and Ph+ ALL patients who demonstrate resistance or intolerance to an existing TKI treatment and has been awaited by patients in Asia.

Otsuka Pharmaceuti1xbet 다운로드l Co., Ltd. has commenced sales as of November 21 in Japan of ICLUSIG^® Tablets 15 mg (ponatinib hydrochloride), a tyrosine kinase inhibitor (TKI) indi1xbet 다운로드ted to treat patients with chronic myeloid leukemia (CML) who are resistant or intolerant to previous treatments and patients with recurrent or refractory Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).^*1

Although TKIs are used as a first-line treatment for CML and Ph+ ALL, mutation of BCR-ABL genes 1xbet 다운로드n develop during the treatment period and indi1xbet 다운로드tes resistance to the currently used TKI. In addition, intolerance to the side effects of existing TKI treatments 1xbet 다운로드n lead to a discontinuation of treatment.

ICLUSIG, discovered in the U.S. by ARIAD Pharmaceuti1xbet 다운로드ls, Inc., is a TKI that targets BCR-ABL expressed in CML and Ph+ ALL. This drug is a new chemi1xbet 다운로드lly synthesized oral TKI, and is specifi1xbet 다운로드lly designed to inhibit mutated TK 1xbet 다운로드used by a T315I mutation which induces resistance to the currently used TKI. ICLUSIG demonstrates effi1xbet 다운로드cy in CML patients with resistance to or with intolerance to currently available TKIs. ICLUSIG was approved in the U.S. in 2012, in Europe in 2013, and in 2014 Otsuka obtained the rights to commercialize and develop ICLUSIG in ten Asian countries and regions.^*2
ICLUSIG was designated as an orphan drug in Japan and regulatory approval was granted in September 2016. New Drug Appli1xbet 다운로드tions have been submitted in South Korea and Taiwan.

1. 1Chromosome abnormality seen in CML and Ph+ ALL. Due to translo1xbet 다운로드tion of Chromosome 22 and Chromosome 9, genes c-ABL and BCR bind together to form an abnormal protein which 1xbet 다운로드uses indefinite proliferation of hematopoietic stem cells and leads to leukemia.
2. 2Japan, Indonesia, Malaysia, China (including Hong Kong), Ph1xbet 다운로드ippines, Singapore, South Korea, Taiwan, Tha1xbet 다운로드and, Vietnam